JP2022554277A5 - - Google Patents
Info
- Publication number
- JP2022554277A5 JP2022554277A5 JP2022525291A JP2022525291A JP2022554277A5 JP 2022554277 A5 JP2022554277 A5 JP 2022554277A5 JP 2022525291 A JP2022525291 A JP 2022525291A JP 2022525291 A JP2022525291 A JP 2022525291A JP 2022554277 A5 JP2022554277 A5 JP 2022554277A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025063020A JP2025106418A (ja) | 2019-10-30 | 2025-04-07 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928092P | 2019-10-30 | 2019-10-30 | |
| US62/928,092 | 2019-10-30 | ||
| US202063068215P | 2020-08-20 | 2020-08-20 | |
| US63/068,215 | 2020-08-20 | ||
| PCT/US2020/058411 WO2021087399A1 (en) | 2019-10-30 | 2020-10-30 | Treatment of ocular diseases using endothelin receptor antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063020A Division JP2025106418A (ja) | 2019-10-30 | 2025-04-07 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022554277A JP2022554277A (ja) | 2022-12-28 |
| JP2022554277A5 true JP2022554277A5 (https=) | 2023-11-07 |
| JPWO2021087399A5 JPWO2021087399A5 (https=) | 2023-11-07 |
| JP7664239B2 JP7664239B2 (ja) | 2025-04-17 |
Family
ID=75715356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525291A Active JP7664239B2 (ja) | 2019-10-30 | 2020-10-30 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| JP2025063020A Pending JP2025106418A (ja) | 2019-10-30 | 2025-04-07 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063020A Pending JP2025106418A (ja) | 2019-10-30 | 2025-04-07 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US11738007B2 (https=) |
| EP (2) | EP4050997A4 (https=) |
| JP (2) | JP7664239B2 (https=) |
| CN (2) | CN118203574A (https=) |
| AU (1) | AU2020373065A1 (https=) |
| CA (1) | CA3158767A1 (https=) |
| IL (1) | IL292350A (https=) |
| MX (1) | MX2022005063A (https=) |
| WO (1) | WO2021087399A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| WO2021087399A1 (en) | 2019-10-30 | 2021-05-06 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| CN115103842A (zh) | 2020-02-06 | 2022-09-23 | 珀弗斯治疗股份有限公司 | 用于治疗眼部疾病的组合物 |
| CA3218251A1 (en) * | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
| AU2022264438A1 (en) * | 2021-04-30 | 2023-11-23 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| EP4346720A4 (en) | 2021-05-28 | 2025-01-01 | Sight Sciences, Inc. | INTRAOCULAR DEVICES, SYSTEMS AND METHODS |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993020784A1 (en) * | 1992-04-10 | 1993-10-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
| US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| JPH0959173A (ja) * | 1995-08-21 | 1997-03-04 | Santen Pharmaceut Co Ltd | 毛様体筋緊張緩和剤 |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| JP2004525890A (ja) * | 2001-02-02 | 2004-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤 |
| US20030176356A1 (en) * | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US20070260203A1 (en) | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| EP2545920A1 (en) | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| CA2759795C (en) | 2009-04-30 | 2016-11-29 | Midwestern University | Method and composition for treating diabetic ketoacidosis |
| WO2010144477A2 (en) | 2009-06-12 | 2010-12-16 | Auspex Pharmaceuticals, Inc. | Sulfonylurea modulators of endothelin receptor |
| EP2558103A4 (en) | 2010-04-12 | 2013-09-25 | R Tech Ueno Ltd | PHARMACEUTICAL COMPOSITION FOR TREATING A MACULAR DERM |
| UA117274C2 (uk) * | 2013-12-19 | 2018-07-10 | Тасос Гєоргіу | Спосіб лікування, зменшення інтенсивності або профілактити захворювань, обумовлених ураженням зорового нерва |
| ES2584534B1 (es) * | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| KR20180021741A (ko) * | 2015-05-29 | 2018-03-05 | 에쥐 세라피틱스, 인코포레이티드 | 시각 손실을 감소시키기 위한 조성물 및 방법 |
| WO2017217967A1 (en) * | 2016-06-13 | 2017-12-21 | Noveome Biotherapeutics, Inc. | Novel methods for delivering therapeutic agents to the eye via nasal passages |
| WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| SG11201912267SA (en) * | 2017-06-19 | 2020-01-30 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| EP3654941A1 (en) * | 2017-07-17 | 2020-05-27 | Keith Roizman | Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases |
| WO2019210194A1 (en) * | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| WO2021087399A1 (en) | 2019-10-30 | 2021-05-06 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| CN115103842A (zh) * | 2020-02-06 | 2022-09-23 | 珀弗斯治疗股份有限公司 | 用于治疗眼部疾病的组合物 |
| CA3218251A1 (en) | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
-
2020
- 2020-10-30 WO PCT/US2020/058411 patent/WO2021087399A1/en not_active Ceased
- 2020-10-30 EP EP20881057.2A patent/EP4050997A4/en active Pending
- 2020-10-30 CN CN202410236817.2A patent/CN118203574A/zh active Pending
- 2020-10-30 IL IL292350A patent/IL292350A/en unknown
- 2020-10-30 EP EP22176530.8A patent/EP4094759A1/en active Pending
- 2020-10-30 MX MX2022005063A patent/MX2022005063A/es unknown
- 2020-10-30 AU AU2020373065A patent/AU2020373065A1/en active Pending
- 2020-10-30 CN CN202080076957.8A patent/CN114786480B/zh active Active
- 2020-10-30 CA CA3158767A patent/CA3158767A1/en active Pending
- 2020-10-30 JP JP2022525291A patent/JP7664239B2/ja active Active
-
2022
- 2022-04-29 US US17/733,216 patent/US11738007B2/en active Active
- 2022-04-29 US US17/733,210 patent/US20220257505A1/en not_active Abandoned
-
2023
- 2023-06-30 US US18/345,514 patent/US20240189288A1/en active Pending
-
2024
- 2024-12-10 US US18/976,033 patent/US20250099435A1/en active Pending
-
2025
- 2025-04-07 JP JP2025063020A patent/JP2025106418A/ja active Pending
- 2025-11-21 US US19/397,828 patent/US20260076948A1/en active Pending